Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  BioMarin Pharmaceutical    BMRN

BIOMARIN PHARMACEUTICAL (BMRN)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/14/2018 06/15/2018 06/18/2018 06/19/2018 06/20/2018 Date
89.98(c) 97.6(c) 95.58(c) 95.62(c) 98.34(c) Last
1 284 197 4 737 996 1 995 541 1 695 224 1 251 248 Volume
+1.14% +8.47% -2.07% +0.04% +2.84% Change
More quotes
Financials (USD)
Sales 2018 1 499 M
EBIT 2018 -111 M
Net income 2018 -126 M
Finance 2018 155 M
Yield 2018 -
Sales 2019 1 731 M
EBIT 2019 44,5 M
Net income 2019 31,9 M
Finance 2019 101 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 635,35
EV / Sales2018 11,2x
EV / Sales2019 9,70x
Capitalization 16 890 M
More Financials
Company
BioMarin Pharmaceutical, Inc. is a biotechnology company, which develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions.Its products include BioMarin, Brineura, Firdapse, Kuvan, Naglazyme, and Vimizim.The company was founded by... 
Sector
Pharmaceuticals
Calendar
08/01Earnings Release
More about the company
Surperformance© ratings of BioMarin Pharmaceutical
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOMARIN PHARMACEUTICAL
06/19BIOMARIN PHARMACEUTICAL : Free Technical Research on BioPharmX and Three More Bi..
AC
06/18BIOMARIN PHARMACEUTICAL : Doses First Participant in Phase 2 Study of Vosoritide..
AQ
06/15NASDAQ 100 MOVERS : Adbe, bmrn
AQ
06/15BIOMARIN PHARMACEUTICAL : Doses First Participant in Phase 2 Study of Vosoritide..
AQ
06/14BIOMARIN PHARMACEUTICAL : Receives Milestone Payments from Pfizer for Talazopari..
AQ
06/14BIOMARIN PHARMACEUTICAL : Doses First Participant in Phase 2 Study of Vosoritide..
PR
06/08BIOMARIN PHARMACEUTICAL INC : Submission of Matters to a Vote of Security Holder..
AQ
06/08BIOMARIN PHARMACEUTICAL : Receives Milestone Payments from Pfizer for Talazopari..
AQ
06/07Pfizer's talazoparib under review in U.S., EU
AQ
06/07BIOMARIN PHARMACEUTICAL : Receives Milestone Payments from Pfizer for Talazopari..
PR
More news
Sector news : Biopharmaceuticals
02:59pGILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
08:48aRoche to Buy Rest of Cancer Firm -- WSJ
DJ
08:16aSHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
08:02aLatecomer Sanofi looks to catch next wave of cancer therapies
RE
07:25aMerck KGaA Partners With Alibaba Health in China
DJ
More sector news : Biopharmaceuticals
Latest Tweets
07:49aInvestors Sell BioMarin Pharmaceutical $BMRN on Strength After Insider Sellin.. 
06/19BioMarin Pharmaceutical Inc. $BMRN SVP Brian Mueller Sells 2,021 Shares  
06/19BioMarin Pharmaceutical Inc. $BMRN Insider Sells $2,790,000.00 in Stock  
06/17BioMarin Pharmaceutical $BMRN Trading 0% Higher  
06/16?FRIDAY'S SIZE SPREADS & COMBOS: $F $C $DXC $BURL $YPF $HST $BMRN $MS $EA..
1
More tweets
Qtime:121
News from SeekingAlpha
06/11CRISPR/Cas9 gene editors weigh on gene therapy stocks 
06/093 THINGS IN BIOTECH, JUNE 8 : Ascend Ye PARP Inhibitors 
06/07BioMarin earns $20M in milestones from Pfizer on talazoparib filings 
05/29BioMarin Keeps The FDA Approval Train Rolling 
05/283 THINGS IN BIOTECH, MAY 28 : Making Deals In The Asian Market 
Chart BIOMARIN PHARMACEUTICAL
Duration : Period :
BioMarin Pharmaceutical Technical Analysis Chart | BMRN | US09061G1013 | 4-Traders
Technical analysis trends BIOMARIN PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 114 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Jean-Jacques Bienaimé Chairman & Chief Executive Officer
Daniel K. Spiegelman Chief Financial Officer & Executive Vice President
Eduardo E. Von Pervieux Chief Information Officer & Vice President
Leonard E. Post Chief Scientific Officer
Elaine J. Heron Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
BIOMARIN PHARMACEUTICAL7.19%16 890
CSL LIMITED30.59%64 342
BIOGEN-8.33%61 007
ALEXION PHARMACEUTICALS1.94%26 404
GRIFOLS9.48%19 151
CELLTRION HEALTHCARE CO LTD--.--%14 354